{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:38:44Z","timestamp":1787787524496,"version":"build-2784847793"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>More than half of new cases of hepatocellular carcinoma (HCC) and associated deaths occurring annually worldwide are recorded in China. Chinese patients with HCC exhibit special characteristics in terms of etiology, leading to differences in prognosis versus Western patients. In recent years, several angiogenesis inhibitors were approved, and immune checkpoint blockers (ICBs) were recommended as second-line therapy for advanced HCC. In addition, the recent success of a combination of atezolizumab with bevacizumab signals resulted in an essential change in the first-line treatment of HCC. We investigated the characteristics of patients with HCC in China and summarized the rapidly emerging relevant clinical data, which relate to the prospects and challenges associated with the use of ICBs in this setting. We further evaluated the efficacy of ICBs in Chinese patients with HCC based on data obtained from global trials, and discussed possible factors influencing the effectiveness of ICBs in patients with HCC in China. Immunotherapy offers new options for the treatment of advanced HCC, though responses varied between patients. Currently, there is a need to discover specific biomarkers for the accurate identification of patients who would more likely benefit from immunotherapy. Furthermore, investigation of patient characteristics in different countries is necessary to provide a clinical practice basis and reference value for the diagnosis and treatment of HCC.<\/jats:p>","DOI":"10.3389\/fonc.2022.764923","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T08:05:55Z","timestamp":1646899555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity"],"prefix":"10.3389","volume":"12","author":[{"given":"Yaoqiang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xibo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing Cancer Survival in China During 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region With Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil\/Leucovorin Versus Doxorubicin as Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27969","article-title":"World-Wide Relative Contribution of Hepatitis B and C Viruses in Hepatocellular Carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112184","article-title":"Comparison of Clinical Manifestations and Outcomes Between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort","volume":"9","author":"Sinn","year":"2014","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00364.x","article-title":"Effect of the Etiology of Viral Cirrhosis on the Survival of Patients With Hepatocellular Carcinoma","volume":"101","author":"Cantarini","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27246","article-title":"Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, Anti-Tumour Activity, and Pharmacokinetics of Fixed-Dose SHR-1210, an Anti-PD-1 Antibody in Advanced Solid Tumours: A Dose-Escalation, Phase 1 Study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","article-title":"Results From a Global Phase 2 Study of Tislelizumab, an Investigational PD-1 Antibody","volume-title":"Patients With Previously Treated Advanced Hepatocellular Carcinoma","author":"Ducreux","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab Versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000515553","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination With Apatinib in Patients With Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-Label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e16146","article-title":"Sintilimab Plus Anlotinib as First-Line Therapy in Patients (Pts) With Advanced Hepatocellular Carcinoma (aHCC)","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.3079","article-title":"Preliminary Results of Sintilimab Plus Different Dose of IBI305 (Anti-VEGF Monoclonal Antibody) in Patients With Advanced Hepatocellular Carcinoma: A Phase Ib Study","author":"Zhang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab Plus a Bevacizumab Biosimilar (IBI305) Versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in Combination With Pembrolizumab in Patients With Advanced Renal Cell Cancer: A Non-Randomised, Open-Label, Dose-Finding, and Dose-Expansion Phase 1b Trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4074","article-title":"Safety and Clinical Activity of 1L Atezolizumab + Bevacizumab in a Phase Ib Study in Hepatocellular Carcinoma (HCC)","volume":"36","author":"Stein","year":"2018","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 Combined With Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4076","article-title":"Update on Overall Survival (OS) of RESCUE: An Open-Label, Phase 2 Trial of Camrelizumab (C) in Combination With Apatinib (A) in Patients With Advanced Hepatocellular Carcinoma (HCC)","volume":"39","author":"Zhang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1159\/000505189","article-title":"A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab Plus Bevacizumab Combination Therapy","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated Overall Survival (OS) Data From a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) Versus Sorafenib (Sor) in Patients (Pts) With Unresectable Hepatocellular Carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000513486","article-title":"Atezolizumab Plus Bevacizumab Versus Sorafenib in the Chinese Subpopulation With Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","volume":"10","author":"Qin","year":"2021","journal-title":"Liver Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive Value of Immunogenic Cell Death Biomarkers HMGB1, sRAGE, and DNase in Liver Cancer Patients Receiving Transarterial Chemoembolization Therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumour Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S187121","article-title":"The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy With Immunotherapy in Hepatocellular Carcinoma","volume":"7","author":"Singh","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.525","article-title":"Nivolumab (NIVO) and Drug Eluting Bead Transarterial Chemoembolization (Deb-TACE): Preliminary Results From a Phase I Study of Patients (Pts) With Liver Limited Hepatocellular Carcinoma (HCC)","volume":"38","author":"Harding","year":"2020","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined Effects of Yttrium-90 Transarterial Radioembolization Around Immunotherapy for Hepatic Metastases From Uveal Melanoma: A Preliminary Retrospective Case Series","volume":"29","author":"Zheng","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4083","article-title":"Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment With Trans-Arterial Radioembolization Followed by Sorafenib and Nivolumab","volume":"11","author":"Adcock","year":"2019","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S298538","article-title":"Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma","volume":"8","author":"Mei","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, Toripalimab, Plus Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0192","article-title":"Real-World Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma","volume":"13","author":"Liu","year":"2021","journal-title":"Immunotherapy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(01)00130-1","article-title":"Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017813","article-title":"Elemene Injection Combined With Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Meta-Analysis","volume":"98","author":"Yao","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B45","article-title":"Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Transcatheter Hepatic Arterial Chemoembolization in Treatment of Liver Cancer: A Bayesian Network Meta-Analysis","volume":"40","author":"Zhang","year":"2020","journal-title":"J Tradit Chin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/1534735417716302","article-title":"Use of Complementary Traditional Chinese Medicines by Adult Cancer Patients in Taiwan: A Nationwide Population-Based Study","volume":"17","author":"Kuo","year":"2018","journal-title":"Integr Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-315983","article-title":"Effect of Huaier Granule on Recurrence After Curative Resection of HCC: A Multicentre, Randomised Clinical Trial","volume":"67","author":"Chen","year":"2018","journal-title":"Gut"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-010-0109-9","article-title":"Short-Term Effect of Combined Therapy With Jinlong Capsule and Transcatheter Arterial Chemoembolization on Patients With Primary Hepatic Carcinoma and Its Influence on Serum Osteopontin Expression","volume":"16","author":"Wu","year":"2010","journal-title":"Chin J Integr Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110820","article-title":"Anti-Tumor Activities and Mechanisms of Traditional Chinese Medicines Formulas: A Review","volume":"132","author":"Fan","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23384","article-title":"Contemporary Clinical Research of Traditional Chinese Medicines for Chronic Hepatitis B in China: An Analytical Review","volume":"51","author":"Zhang","year":"2010","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.129","article-title":"Aristolochic Acid Nephropathy: A Worldwide Problem","volume":"74","author":"Debelle","year":"2008","journal-title":"Kidney Int"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701248104","article-title":"Aristolochic Acid and the Etiology of Endemic (Balkan) Nephropathy","volume":"104","author":"Grollman","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1819-3","article-title":"Balkan Endemic Nephropathy: An Update on Its Aetiology","volume":"90","author":"Stiborov\u00e1","year":"2016","journal-title":"Arch Toxicol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30863","article-title":"The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers","volume":"71","author":"Lu","year":"2020","journal-title":"Hepatology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan6446","article-title":"Aristolochic Acids and Their Derivatives Are Widely Implicated in Liver Cancers in Taiwan and Throughout Asia","volume":"9","author":"Ng","year":"2017","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-13-0179","article-title":"Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies","volume":"2","author":"Vandeven","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The Yin and Yang of Evasion and Immune Activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti-PD-1\/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98674","article-title":"TSC2-Deficient Tumors Have Evidence of T Cell Exhaustion and Respond to Anti-PD-1\/Anti-CTLA-4 Immunotherapy","volume":"3","author":"Liu","year":"2018","journal-title":"JCI Insight"},{"key":"B63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12885-021-07978-3","article-title":"The Association of Sex-Biased ATRX Mutation in Female Gastric Cancer Patients With Enhanced Immunotherapy-Related Anticancer Immunity","volume":"21","author":"Ge","year":"2021","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846821","article-title":"The Lysine-Specific Methyltransferase KMT2C\/MLL3 Regulates DNA Repair Components in Cancer","volume":"20","author":"Rampias","year":"2019","journal-title":"EMBO Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1839","article-title":"Comprehensive Analysis of Age-Related Somatic Mutation Profiles in Chinese Young Lung Adenocarcinoma Patients","volume":"8","author":"Yang","year":"2019","journal-title":"Cancer Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3649","article-title":"Integration of Comprehensive Genomic Profiling, Tumor Mutational Burden, and PD-L1 Expression to Identify Novel Biomarkers of Immunotherapy in Non-Small Cell Lung Cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Cancer Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3778","article-title":"Immune Exclusion-Wnt\/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC","volume":"25","author":"Pinyol","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1394142","article-title":"Transarterial Chemoembolization and Radioembolization","volume":"34","author":"Sangro","year":"2014","journal-title":"Semin Liver Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3978\/j.issn.1000-9604.2015.03.03","article-title":"Transcatheter Embolization Therapy in Liver Cancer: An Update of Clinical Evidences","volume":"27","author":"W\u00e1ng","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.4171","article-title":"Effect of Transcatheter Arterial Chemoembolization on Cellular Immune Function and Regulatory T Cells in Patients With Hepatocellular Carcinoma","volume":"12","author":"Liao","year":"2015","journal-title":"Mol Med Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060444","article-title":"Increased Circulating Th17 Cells After Transarterial Chemoembolization Correlate With Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study","volume":"8","author":"Liao","year":"2013","journal-title":"PloS One"},{"key":"B72","article-title":"Changes of Immune Function in Liver Cancer Patients After Transcatheter Arterial Chemoembolizaton Combined With Interstitial Therapy","volume":"29","author":"Quan","year":"2009","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/his.14317","article-title":"Transarterial Chemoembolisation Enhances Programmed Death-1 and Programmed Death-Ligand 1 Expression in Hepatocellular Carcinoma","volume":"79","author":"Montasser","year":"2021","journal-title":"Histopathology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cca.2020.09.026","article-title":"Elevated Soluble Programmed Death-Ligand 1 Levels Indicate Immunosuppression and Poor Prognosis in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization","volume":"511","author":"Ma","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12270","article-title":"Traditional Chinese Medicine and Cancer: History, Present Situation, and Development","volume":"6","author":"Liu","year":"2015","journal-title":"Thorac Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00648","article-title":"Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms","volume":"10","author":"Han","year":"2019","journal-title":"Front Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216135","article-title":"Worldwide Research Trends on Aristolochic Acids (1957-2017): Suggestions for Researchers","volume":"14","author":"Zhou","year":"2019","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12789","article-title":"Recognition of the Toxicity of Aristolochic Acid","volume":"44","author":"Zhang","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02685-7","article-title":"Associations Among the Mutational Landscape, Immune Microenvironment, and Prognosis in Chinese Patients With Hepatocellular Carcinoma","volume":"70","author":"Hu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12992","article-title":"Genomic and Oncogenic Preference of HBV Integration in Hepatocellular Carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203312","article-title":"Transcriptional Repression of the Human P53 Gene by Hepatitis B Viral X Protein","volume":"19","author":"Lee","year":"2000","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2003.022","article-title":"Transcriptional Repression of the Human P53 Gene by Hepatitis B Viral Core Protein (HBc) in Human Liver Cells","volume":"384","author":"Kwon","year":"2003","journal-title":"Biol Chem"},{"key":"B85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.explore.2010.10.002","article-title":"Meta-Analysis: Traditional Chinese Medicine for Improving Immune Response in Patients With Unresectable Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization","volume":"7","author":"Meng","year":"2011","journal-title":"Explore (NY)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular Carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.764923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T08:06:01Z","timestamp":1646899561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.764923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":86,"alternative-id":["10.3389\/fonc.2022.764923"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.764923","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"article-number":"764923"}}